Recursion Pharmaceuticals (NASDAQ:RXRX) has aligned with the U.S. Food and Drug Administration on the primary endpoint for a planned Phase III study of its experimental treatment for familial ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
RXRX is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.10 since the market last closed. This is a 3.72% ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Since the launch of the Crossword in 1942, The Times has captivated solvers by providing engaging word and logic games. In 2014, we introduced the Mini Crossword — followed by Spelling Bee, Letter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results